Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Lilly gets FDA review for empagliflozin in chronic kidney disease

By Brian Buntz | January 20, 2023

Eli Lilly in the Drug Discovery & Development Pharma 50The FDA has accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets as a potential therapy to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD).

Some 37 million people in the U.S. have CKD.

Lilly (NYSE:LLY) is developing the drug with Boehringer Ingelheim.

The supplemental New Drug Application includes data from the landmark EMPA-KIDNEY Phase 3 study, which found that empagliflozin led to a significant reduction in the risk of kidney disease progression or cardiovascular death in adults with CKD. In the study, the drug on top of  standard of care reduced the risk of kidney disease progression or cardiovascular death in adults by 28% compared with placebo.

EMPA-KIDNEY is an abbreviation of Empagliflozin in the Management of Patients with Advanced Chronic Kidney Disease.

The randomized, double-blind, placebo-controlled study (NCT03594110) enrolled more than 6,600 patients.

Empagliflozin belongs to a class of drugs known as sodium-glucose cotransporter 2 (SGLT2) inhibitors, which prevent kidneys from reabsorbing glucose back into the bloodstream. Empagliflozin thus causes patients to excrete extra glucose in the urine.

The reduction in blood sugar levels may also slow the progression of kidney disease. Empagliflozin also could help the body remove excess fluid and electrolytes, which can help people with CKD reduce the volume of fluid in the body and decrease kidney workload.

FDA first approved empagliflozin to treat type 2 diabetes in 2014. Indications followed for reducing cardiovascular death in adults with type 2 diabetes, treating adults with heart failure with reduced ejection fraction and heart failure regardless of left ventricular ejection fraction.

In the EMPA-KIDNEY study, the safety data for empagliflozin was in line with prior studies.

Empagliflozin won FDA Fast Track designation in March 2020 to lower the risk of kidney disease progression and cardiovascular death in adults with CKD.

This study was a randomized, double-blind, placebo-controlled trial that enrolled over 3000 participants with stages 3b to 4 CKD and type 2 diabetes.


Filed Under: Cardiovascular, Drug Discovery and Development, Nephrology/urology
Tagged With: Boehringer Ingelheim, Eli Lilly, empagliflozin, Jardiance, Lilly
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
Illustration of the thought processes in the brain
From gene therapy to vaccines to mitochondrial rescue, the quest for more effective neurodegenerative therapies faces mixed outcomes in 2024
hemodialysis in people on the equipment
Beyond diabetes and obesity: Can GLP-1 therapies also transform chronic disease treatment?
Novo Nordisk in the Drug Discovery & Development Pharma 50
Novo Nordisk stops once-weekly semaglutide kidney outcomes trial early following interim analysis
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE